Effects of astaxanthin supplementation in healthy and obese dogs.
anti-oxidative activity
astaxanthin
lipid metabolism
liver function
obese dogs
Journal
Veterinary medicine (Auckland, N.Z.)
ISSN: 2230-2034
Titre abrégé: Vet Med (Auckl)
Pays: New Zealand
ID NLM: 101724251
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
13
3
2019
pubmed:
13
3
2019
medline:
13
3
2019
Statut:
epublish
Résumé
Since astaxanthin (ASX) has potent anti-oxidative effects with inhibitory action of lipid peroxidation and singlet oxygen quenching activity, it is widely used as a functional food for keeping good health in human. Obesity is a risk factor for various metabolic disorders. It is characterized by low-grade chronic inflammation based on oxidative stress by excessively produced ROS. From the point of preventive medicine, natural compounds have been proposed as potential therapeutic agents in the prevention of metabolic disorder in companion animals. The purpose of this study is to evaluate the effects of ASX supplementation in healthy and obese dogs. Ten healthy beagle dogs and 5 clinically obese dogs were used in this study. The healthy beagle dogs were randomly divided into 2 groups as follows: control and test groups. The test group dogs received ASX supplementation mixed with the food for 6 weeks. Five clinically obese dogs received ASX supplementation for 8 weeks. Metabolites, hormones and enzymes were measured before and after ASX supplementation. In the healthy dog groups, after 6 weeks, plasma triglyceride (TG) and malondialdehyde concentrations and lactate dehydrogenase (LDH) values significantly decreased in the test group. There was no significant difference in the control group. In clinically obese dogs, plasma TG concentration decreased after 8 weeks of ASX supplementation. Plasma alanine aminotransferase and LDH values clearly decreased in all 5 dogs and 4 dogs out of 5 dogs, respectively. ASX supplementation (0.3 mg/kg body weight/day) for 6 weeks in healthy dogs and 8 weeks in obese dogs induced the elevation of antioxidant function and of liver function by ameliorating lipid metabolism.
Sections du résumé
BACKGROUND
BACKGROUND
Since astaxanthin (ASX) has potent anti-oxidative effects with inhibitory action of lipid peroxidation and singlet oxygen quenching activity, it is widely used as a functional food for keeping good health in human. Obesity is a risk factor for various metabolic disorders. It is characterized by low-grade chronic inflammation based on oxidative stress by excessively produced ROS. From the point of preventive medicine, natural compounds have been proposed as potential therapeutic agents in the prevention of metabolic disorder in companion animals. The purpose of this study is to evaluate the effects of ASX supplementation in healthy and obese dogs.
MATERIALS AND METHODS
METHODS
Ten healthy beagle dogs and 5 clinically obese dogs were used in this study. The healthy beagle dogs were randomly divided into 2 groups as follows: control and test groups. The test group dogs received ASX supplementation mixed with the food for 6 weeks. Five clinically obese dogs received ASX supplementation for 8 weeks. Metabolites, hormones and enzymes were measured before and after ASX supplementation.
RESULTS
RESULTS
In the healthy dog groups, after 6 weeks, plasma triglyceride (TG) and malondialdehyde concentrations and lactate dehydrogenase (LDH) values significantly decreased in the test group. There was no significant difference in the control group. In clinically obese dogs, plasma TG concentration decreased after 8 weeks of ASX supplementation. Plasma alanine aminotransferase and LDH values clearly decreased in all 5 dogs and 4 dogs out of 5 dogs, respectively.
CONCLUSION
CONCLUSIONS
ASX supplementation (0.3 mg/kg body weight/day) for 6 weeks in healthy dogs and 8 weeks in obese dogs induced the elevation of antioxidant function and of liver function by ameliorating lipid metabolism.
Identifiants
pubmed: 30859086
doi: 10.2147/VMRR.S186202
pii: vmrr-10-029
pmc: PMC6385744
doi:
Types de publication
Journal Article
Langues
eng
Pagination
29-35Déclaration de conflit d'intérêts
Disclosure Kumi Tominaga is a resercher working in AstaReal Co.Ltd. The authors report no other conflicts of interest in this work.
Références
Gastroenterology. 1999 Jun;116(6):1413-9
pubmed: 10348825
J Clin Endocrinol Metab. 2001 Mar;86(3):1306-12
pubmed: 11238525
Endocr Rev. 2002 Oct;23(5):599-622
pubmed: 12372842
Br Poult Sci. 2004 Feb;45(1):133-8
pubmed: 15115211
Comp Biochem Physiol C Toxicol Pharmacol. 2004 Mar;137(3):227-36
pubmed: 15171947
Biosci Biotechnol Biochem. 2007 Apr;71(4):893-9
pubmed: 17420580
Diabetes. 2008 Oct;57(10):2595-602
pubmed: 18633101
Toxicology. 2010 Jan 12;267(1-3):147-53
pubmed: 19900500
Diabetologia. 2010 Jul;53(7):1270-87
pubmed: 20361178
Physiol Chem Phys Med NMR. 1990;22(1):27-38
pubmed: 2084711
Obes Rev. 2012 Jan;13(1):17-26
pubmed: 21831233
Food Funct. 2012 Feb;3(2):120-6
pubmed: 22089895
Mediators Inflamm. 2013;2013:513251
pubmed: 23476105
Circulation. 2015 Dec 1;132(22):2134-45
pubmed: 26362633
Front Vet Sci. 2017 Feb 14;4:17
pubmed: 28261588
J Diet Suppl. 2018 Jan 2;15(1):42-54
pubmed: 28489954
World J Gastroenterol. 2017 Jun 21;23(23):4146-4157
pubmed: 28694655
Pharmacognosy Res. 2017 Dec;9(Suppl 1):S84-S91
pubmed: 29333048
Front Nutr. 2018 Jan 18;4:76
pubmed: 29404334
Mol Vis. 2018 Mar 07;24:201-217
pubmed: 29527116
Biochem Biophys Res Commun. 2018 Jun 7;500(3):797-803
pubmed: 29684344
J Am Coll Nutr. 2018 Apr 27;:1-8
pubmed: 29702041
J Nutr Biochem. 2018 Jul;57:170-179
pubmed: 29734116
J Diabetes Res. 2018 Mar 21;2018:6730315
pubmed: 29744366
Curr Hypertens Rep. 2018 May 9;20(5):45
pubmed: 29744660
World J Surg. 2018 Nov;42(11):3651-3657
pubmed: 29766228
Int J Obes (Lond). 2018 Dec;42(12):2012-2021
pubmed: 29769704
Nutrients. 2018 Aug 21;10(9):null
pubmed: 30134611
Vet Rec. 1986 Apr 5;118(14):391-6
pubmed: 3716092